Hairy cell leukemia, version 2.2018: Clinical Practice Guidelines in Oncology Journal Article


Authors: Wierda, W. G.; Byrd, J. C.; Abramson, J. S.; Bhat, S.; Bociek, G.; Brander, D.; Brown, J.; Chanan-Khan, A.; Coutre, S. E.; Davis, R. S.; Fletcher, C. D.; Hill, B.; Kahl, B. S.; Kamdar, M.; Kaplan, L. D.; Khan, N.; Kipps, T. J.; Lancet, J.; Ma, S.; Malek, S.; Mosse, C.; Shadman, M.; Siddiqi, T.; Stephens, D.; Wagner, N.; Zelenetz, A. D.; Dwyer, M. A.; Sundar, H.
Article Title: Hairy cell leukemia, version 2.2018: Clinical Practice Guidelines in Oncology
Abstract: Hairy cell leukemia (HCL) is a rare type of indolent B-cell leukemia, characterized by symptoms of fatigue and weakness, or-ganomegaly, pancytopenia, and recurrent opportunistic infections. Classic HCL should be considered a distinct clinical entity separate from HCLvariant (HCLv), which is associated with a more aggressive disease course and may not respond to standard HCL therapies. Somatic hypermutation in the IGHV gene is present in most patients with HCL. The BRAF V600E mutation has been reported in most patients with classic HCL but not in those with other B-cell leukemias or lymphomas. Therefore, it is necessary to distinguish HCLv from classic HCL. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of classic HCL. © JNCCN - Journal of the National Comprehensive Cancer Network.
Keywords: treatment response; review; cancer growth; hepatitis b; multimodality cancer therapy; cancer diagnosis; cancer palliative therapy; consensus; evidence based practice; practice guideline; oncology; hepatitis b virus; virus reactivation; hairy cell leukemia; randomized controlled trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); multicenter study (topic); human
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 15
Issue: 11
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2017-11-01
Start Page: 1414
End Page: 1427
Language: English
DOI: 10.6004/jnccn.2017.0165
PROVIDER: scopus
PUBMED: 29118233
DOI/URL:
Notes: Review -- Export Date: 2 January 2018 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Andrew D Zelenetz
    768 Zelenetz